Plasmapheresis and immunosuppressive drug therapy in scleroderma

Area of Science:

• Rheumatology
• Immunology
• Dermatology

Background:

• Scleroderma is a complex autoimmune disease characterized by skin thickening and internal organ involvement.
• Current treatments for scleroderma have limited efficacy, necessitating exploration of novel therapeutic strategies.
• Circulating factors and immune system dysregulation are implicated in scleroderma pathogenesis.

Purpose of the Study:

• To evaluate the efficacy of plasmapheresis in conjunction with immunosuppressive therapy (prednisone and cyclophosphamide) for scleroderma patients.
• To assess the impact of this combined treatment on clinical symptoms, immunological markers, and tissue pathology.
• To investigate the role of circulating factors in scleroderma progression.

Main Methods:

• An uncontrolled clinical trial involving 15 patients with moderate to severe scleroderma.
• Treatment regimen included plasmapheresis, prednisone, and cyclophosphamide.
• Clinical assessments, laboratory tests (ANA titers, endothelial cell cytotoxic activity, immune complexes), and skin biopsies were performed.

Main Results:

• 14 out of 15 patients showed clinical improvement, including skin loosening, contracture relaxation, and ulcer healing.
• Significant amelioration of gastrointestinal symptoms, polymyositis, and improvements in pulmonary and cardiac function were observed.
• Plasmapheresis reduced antinuclear antibody (ANA) titers, endothelial cell cytotoxic activity, and showed favorable changes in skin biopsies.

Conclusions:

• Combined plasmapheresis and immunosuppressive therapy demonstrated significant clinical benefits in scleroderma patients.
• The findings suggest that circulating factors play a crucial role in scleroderma pathogenesis.
• This therapeutic approach may offer a valuable option for managing moderate to severe scleroderma.